alexa High Frequency of Advanced Hepatic Disease among HIV/HC
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

High Frequency of Advanced Hepatic Disease among HIV/HCV Co-Infected Patients in Cambodia: The HEPACAM Study

Nathalie Lerolle1,5*, Setha Limsreng2,3, Isabelle Fournier-Nicolle4,5, Sowath Ly5, Janin Nouhin6, Bertrand Guillard7, Sreymom Ken6, Anne Dulioust1,2, Pichit Khuon2,3, Jean-François Delfraissy1,2,4, Vara Ouk2,3 and Olivier Segeral1,2

1Assistance Publique - Hôpitaux de Paris (AP-HP), Département de Médecine Interne et Maladies Infectieuses, Centre Hospitalier Universitaire de Bicêtre, 78 rue du Général Leclerc, 94 276 Le Kremlin-Bicêtre, France

2Ensemble pour une Solidarité Thérapeutique Hospitalière En Réseau” (ESTHER), France

3Department of Internal Medicine Division of Infectious Diseases, Calmette Hospital, Phnom Penh, Cambodia

4Agence Nationale de Recherche sur le Sida et les hépatites virales (ANRS), France

5Epidemiology Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia

6Laboratory of HIV/Hepatitis, Institut Pasteur in Cambodia, Phnom Penh, Cambodia

7Clinical Laboratory, Institut Pasteur in Cambodia, Phnom Penh, Cambodia

*Corresponding Author:
Nathalie Lerolle
Assistance Publique - Hôpitaux de Paris (AP-HP)
Département de Médecine Interne et Maladies Infectieuses
Centre Hospitalier Universitaire de Bicêtre
78 rue du Général Leclerc
94 276 Le Kremlin-Bicêtre, France
Tel: 33145212891
Fax: 33145212741
E-mail: [email protected]

Received Date: June 15, 2012; Accepted Date: July 05, 2012; Published Date: July 08, 2012

Citation: Lerolle N, Limsreng S, Fournier-Nicolle I, Ly S, Nouhin J, et al. (2012) High Frequency of Advanced Hepatic Disease among HIV/HCV Co-Infected Patients in Cambodia: The HEPACAM Study (ANRS 12267). J AIDS Clinic Res 3:161. doi:10.4172/2155-6113.1000161

Copyright: © 2012 Lerolle N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Little is known about HIV/Hepatitis C Virus (HCV) co-infection in resource-limited countries, although chronic HCV infection is one of the most relevant comorbidities in HIV population. The aim of this study was to determine the severity of liver disease in a cohort of HIV/HCV co-infected patients followed in Calmette Hospital, Phnom Penh, Cambodia, and to analyse the impact of HCV infection on antiretroviral therapy efficacy and hepatotoxicity.

Methods: HIV patients with positive HCV antibodies were enrolled in this cross-sectional study. HIV monoinfected patients formed the control group. Transverse evaluation of co-infected patients was performed collecting clinical, biological, virological and ultrasonographic data. HIV course, response to antiretroviral therapy and frequency of hepatocytolysis were compared in both groups.

Results: Among 50 HIV patients known with HCV antibodies, 31 (62%) had positive plasma HCV RNA and were included (58% men, median age 44 years). HCV genotype 1 was the most prevalent (68%), followed by genotype 6 (25%). Twelve patients (39%) met clinical, biological and/or ultrasonographic criteria for cirrhosis. FibroTest stage was 3-4 in 16 patients (52%). HIV/HCV co-infected patients demonstrated similar immune restoration and virological response to antiretroviral therapy as the 160 HIV mono-infected patients. Co-infected patients were more likely to have alanine aminotransferase elevation at baseline and to develop grade 2 or 3 hepatocytolysis in the two years after antiretroviral therapy initiation, specifically when nevirapine was used during the first six months of treatment.

Conclusions: HIV/HCV co-infected patients are at increased risk for acquiring severe hepatic fibrosis. HCV coinfection does not affect response to ART. Efavirenz should be preferred to nevirapine in co-infected patients due to hepatotoxicity. Further research is required to target access to appropriate management of HIV/HCV co-infections in resource-limited countries.

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords